MAR 15, 2018 09:00 AM PDT

Multiplex Immunoassay Detection of Alzheimer's Disease Biomarkers in Cerebrospinal Fluid, Plasma, and Serum

Presented At Neuroscience 2018
SPONSORED BY: MilliporeSigma
C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Senior Scientist, MilliporeSigma
    Biography
      Dr. Saporita has over 15 years of experience in protein biochemistry and assay development. He earned his B.S. from University of Missouri and Ph.D. from Northwestern University and received postdoctoral training at Washington University in Saint Louis. As part of the Research & Development team at MilliporeSigma, Dr. Saporita designs new immunoassay kits for protein biomarker detection for several research categories including neuroscience, toxicity, and cell signaling.

    Abstract:

    Monitoring protein biomarkers in cerebrospinal fluid (CSF) of patients with Alzheimer’s Disease (AD) has been highly beneficial to understanding disease progression.  While several CSF biomarkers can reproducibly distinguish normal and diseased samples, CSF is a difficult biological fluid to obtain in research studies.  The need for blood-based biomarkers of AD has driven a continuous search for novel candidates.  Here we report the development of a multiplex immunoassay to quantitatively measure seven proteins present in both CSF and blood that are involved in neurological disease:  Neurogranin, TREM2, ApoE4, FABP3, Ferritin, angiogenin, and prion protein.  Notably, presence of the APOE4 allele is prominently associated with an increased risk for AD, in comparison to the APOE2 and APOE3 alleles.  Although these ApoE isoforms differ at only one or two amino acids, our assay distinguished ApoE4 with minimal cross-reactivity. Using this novel immunoassay, we measured these 7 biomarkers in CSF, plasma, and serum from AD patients and healthy controls.  Additionally, we developed an ultrasensitive Single Molecule Counting (SMC) assay for amyloid beta 1-42 (Aβ42).  This kit could detect the Aβ42 peptide in CSF and plasma at sub-pg/mL concentrations.  This study demonstrates the value of evaluating both novel and established biomarkers of neurodegeneration across distinct sample types.


    Show Resources
    You May Also Like
    SEP 05, 2019 04:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 04:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    JUN 05, 2019 05:00 PM CEST
    C.E. CREDITS
    JUN 05, 2019 05:00 PM CEST
    DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
    NOV 18, 2019 08:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    NOV 18, 2019 08:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: November 18, 2019TIME: 8:00am PST, 11:00am EST, 4:00pm CEWT How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop th...
    JUN 19, 2019 10:00 AM PDT
    JUN 19, 2019 10:00 AM PDT
    DATE: June 19, 2019TIME: 10:00am PDT, 1:00pm EDT As we develop new methods to create more biologically relevant models for research in understanding disease etiology and in...
    AUG 13, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 13, 2019 09:00 AM PDT
    DATE: August 13, 2019TIME: 9:00am PT, 12:00pm ET, 5:00pm BST Molecular complexes are major constituents of cells, hence unraveling their mechanisms is key to fuller comprehension of c...
    APR 09, 2019 09:00 AM PDT
    C.E. CREDITS
    APR 09, 2019 09:00 AM PDT
    DATE: April 9, 2019TIME: 9:00 AM PDTWe will provide a general introduction to the Single-Cell Western Technology (SCW) and then present data from 2 ongoing projects from the Col...
    Loading Comments...
    Show Resources